-
11.发明申请BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS 有权双相异构体取代的吡啶化合物有用作激酶调节剂公开(公告)号：US20150274696A1
公开(公告)日：2015-10-01
申请号：US14441698
申请日：2013-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D401/12 , C07D513/04 , C07D471/04 , C07D417/14 , C07D487/04 , C07D417/12 , C07D413/12
CPC classification number: C07D401/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。
-
12.发明申请NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS 有权新型替代吡唑并吡啶作为CASEIN KINASE 1 D / E抑制剂公开(公告)号：US20150133428A1
公开(公告)日：2015-05-14
申请号：US14541343
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D491/20 , C07D491/147
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
13.发明申请公开(公告)号：US20150045347A1
公开(公告)日：2015-02-12
申请号：US14371281
申请日：2013-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dharmpal S. Dodd , Christopher P. Mussari , Rajeev S. Bhide , Satheesh Kesavan Nair , Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , William J. Pitts , John Hynes
IPC: C07D471/10 , C07D417/14
CPC classification number: C07D471/10 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: (I) wherein: A is an optionally substituted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：（I）其中：A是任选取代的三唑或其立体异构体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
14.发明申请公开(公告)号：US20150011532A1
公开(公告)日：2015-01-08
申请号：US14371456
申请日：2013-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banejee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D471/10
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04
Abstract: Compounds having the following formula: wherein A is, or; and X is N or C—R7, or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：其中A是或; 并且X是N或C-R7，或其对映体，非对映体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
Patent Agency Ranking
公开(公告)号：US10023562B2
公开(公告)日：2018-07-17
申请号：US15480682
申请日：2017-04-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D401/12 , C07D407/14 , C07D405/12 , C07D213/74 , C07D405/14 , C07D401/14 , C07D417/14
Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
公开(公告)号：US20170210730A1
公开(公告)日：2017-07-27
申请号：US15480682
申请日：2017-04-06
Applicant: Bristol-Myers Squibb Company
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D407/14 , C07D213/74 , C07D417/14 , C07D405/14 , C07D401/14 , C07D405/12 , C07D401/12
CPC classification number: C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
![Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors](/abs-image/US/2017/03/21/US09598423B2/abs.jpg.150x150.jpg)
17.发明授权公开(公告)号：US09598423B2
公开(公告)日：2017-03-21
申请号：US15034217
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: A61K31/498 , C07D487/04 , C07D491/147 , C07D487/10 , C07D491/20 , C07D487/20 , C07D519/00
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
18.发明授权Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators 有权用作激酶调节剂的双环杂环取代的吡啶基化合物公开(公告)号：US09546153B2
公开(公告)日：2017-01-17
申请号：US14441698
申请日：2013-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D401/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D513/04 , C07D417/14 , C07D471/04
CPC classification number: C07D401/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。
-
19.发明授权公开(公告)号：US08987311B2
公开(公告)日：2015-03-24
申请号：US14371281
申请日：2013-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Dharmpal S. Dodd , Christopher P. Mussari , Rajeev S. Bhide , Satheesh Kesavan Nair , Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , William J. Pitts , John Hynes
IPC: C07D401/04 , A61K31/44 , C07D471/10 , C07D417/14
CPC classification number: C07D471/10 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: (I) wherein: A is an optionally substituted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：（I）其中：A是任选取代的三唑或其立体异构体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.04 seconds)
